APOEε2 is associated with milder clinical and pathological Alzheimer disease

Alberto Serrano-Pozo, Jing Qian, Sarah E. Monsell, Rebecca Betensky, Bradley T. Hyman

Research output: Contribution to journalArticle

Abstract

Objective The Alzheimer disease (AD) APOE 4 risk allele associates with an earlier age at onset and increased amyloid-β deposition, whereas the protective APOE 2 allele delays the onset and appears to prevent amyloid-β deposition. Yet the clinical and pathological effects of APOE 2 remain uncertain because of its relative rarity. We investigated the effects of APOE 2 and 4 alleles on AD pathology and cognition in a large US data set of well-characterized AD patients. Methods We studied individuals from the National Alzheimer's Coordinating Center autopsy cohort across the entire clinicopathological continuum of AD. Multivariate models were built to examine the associations between APOE alleles and AD neuropathological changes, using the APOE 3/ 3 group as comparator. Mediation analysis was used to estimate the direct and indirect effects of APOE alleles on AD pathology and cognition (Clinical Dementia Rating Sum of Boxes and Mini-Mental State Examination). Results Compared to APOE 3/ 3, APOE 2 is independently associated with lower Braak neurofibrillary tangle (NFT) stages and possibly fewer neuritic plaques, but has no direct effect on cerebral amyloid angiopathy (CAA) severity, whereas APOE 4 is associated with more neuritic plaques and CAA, but has no independent effect on Braak NFT stage. Unadjusted analyses showed marked differences among APOE genotypes with respect to cognitive performance ( 2 > 3 > 4). Mediation analysis suggests that this is largely explained through effects on pathology. Interpretation Even when adjusted for age at onset, symptom duration, and other demographic variables, APOE 2 is associated with milder AD pathology and less severe antemortem cognitive impairment compared to APOE 3 and 4 alleles, suggesting a relative neuroprotective effect of APOE 2 in AD. Ann Neurol 2015;77:917-929

Original languageEnglish (US)
Pages (from-to)917-929
Number of pages13
JournalAnnals of Neurology
Volume77
Issue number6
DOIs
StatePublished - Jan 1 2015

Fingerprint

Alzheimer Disease
Alleles
Cerebral Amyloid Angiopathy
Neurofibrillary Tangles
Amyloid Plaques
Pathology
Age of Onset
Amyloid
Cognition
Clinical Pathology
Neuroprotective Agents
Dementia
Autopsy
Genotype
Demography

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

APOEε2 is associated with milder clinical and pathological Alzheimer disease. / Serrano-Pozo, Alberto; Qian, Jing; Monsell, Sarah E.; Betensky, Rebecca; Hyman, Bradley T.

In: Annals of Neurology, Vol. 77, No. 6, 01.01.2015, p. 917-929.

Research output: Contribution to journalArticle

Serrano-Pozo, Alberto ; Qian, Jing ; Monsell, Sarah E. ; Betensky, Rebecca ; Hyman, Bradley T. / APOEε2 is associated with milder clinical and pathological Alzheimer disease. In: Annals of Neurology. 2015 ; Vol. 77, No. 6. pp. 917-929.
@article{214f66aa858649138aad693780f0a3a3,
title = "APOEε2 is associated with milder clinical and pathological Alzheimer disease",
abstract = "Objective The Alzheimer disease (AD) APOE 4 risk allele associates with an earlier age at onset and increased amyloid-β deposition, whereas the protective APOE 2 allele delays the onset and appears to prevent amyloid-β deposition. Yet the clinical and pathological effects of APOE 2 remain uncertain because of its relative rarity. We investigated the effects of APOE 2 and 4 alleles on AD pathology and cognition in a large US data set of well-characterized AD patients. Methods We studied individuals from the National Alzheimer's Coordinating Center autopsy cohort across the entire clinicopathological continuum of AD. Multivariate models were built to examine the associations between APOE alleles and AD neuropathological changes, using the APOE 3/ 3 group as comparator. Mediation analysis was used to estimate the direct and indirect effects of APOE alleles on AD pathology and cognition (Clinical Dementia Rating Sum of Boxes and Mini-Mental State Examination). Results Compared to APOE 3/ 3, APOE 2 is independently associated with lower Braak neurofibrillary tangle (NFT) stages and possibly fewer neuritic plaques, but has no direct effect on cerebral amyloid angiopathy (CAA) severity, whereas APOE 4 is associated with more neuritic plaques and CAA, but has no independent effect on Braak NFT stage. Unadjusted analyses showed marked differences among APOE genotypes with respect to cognitive performance ( 2 > 3 > 4). Mediation analysis suggests that this is largely explained through effects on pathology. Interpretation Even when adjusted for age at onset, symptom duration, and other demographic variables, APOE 2 is associated with milder AD pathology and less severe antemortem cognitive impairment compared to APOE 3 and 4 alleles, suggesting a relative neuroprotective effect of APOE 2 in AD. Ann Neurol 2015;77:917-929",
author = "Alberto Serrano-Pozo and Jing Qian and Monsell, {Sarah E.} and Rebecca Betensky and Hyman, {Bradley T.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/ana.24369",
language = "English (US)",
volume = "77",
pages = "917--929",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - APOEε2 is associated with milder clinical and pathological Alzheimer disease

AU - Serrano-Pozo, Alberto

AU - Qian, Jing

AU - Monsell, Sarah E.

AU - Betensky, Rebecca

AU - Hyman, Bradley T.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective The Alzheimer disease (AD) APOE 4 risk allele associates with an earlier age at onset and increased amyloid-β deposition, whereas the protective APOE 2 allele delays the onset and appears to prevent amyloid-β deposition. Yet the clinical and pathological effects of APOE 2 remain uncertain because of its relative rarity. We investigated the effects of APOE 2 and 4 alleles on AD pathology and cognition in a large US data set of well-characterized AD patients. Methods We studied individuals from the National Alzheimer's Coordinating Center autopsy cohort across the entire clinicopathological continuum of AD. Multivariate models were built to examine the associations between APOE alleles and AD neuropathological changes, using the APOE 3/ 3 group as comparator. Mediation analysis was used to estimate the direct and indirect effects of APOE alleles on AD pathology and cognition (Clinical Dementia Rating Sum of Boxes and Mini-Mental State Examination). Results Compared to APOE 3/ 3, APOE 2 is independently associated with lower Braak neurofibrillary tangle (NFT) stages and possibly fewer neuritic plaques, but has no direct effect on cerebral amyloid angiopathy (CAA) severity, whereas APOE 4 is associated with more neuritic plaques and CAA, but has no independent effect on Braak NFT stage. Unadjusted analyses showed marked differences among APOE genotypes with respect to cognitive performance ( 2 > 3 > 4). Mediation analysis suggests that this is largely explained through effects on pathology. Interpretation Even when adjusted for age at onset, symptom duration, and other demographic variables, APOE 2 is associated with milder AD pathology and less severe antemortem cognitive impairment compared to APOE 3 and 4 alleles, suggesting a relative neuroprotective effect of APOE 2 in AD. Ann Neurol 2015;77:917-929

AB - Objective The Alzheimer disease (AD) APOE 4 risk allele associates with an earlier age at onset and increased amyloid-β deposition, whereas the protective APOE 2 allele delays the onset and appears to prevent amyloid-β deposition. Yet the clinical and pathological effects of APOE 2 remain uncertain because of its relative rarity. We investigated the effects of APOE 2 and 4 alleles on AD pathology and cognition in a large US data set of well-characterized AD patients. Methods We studied individuals from the National Alzheimer's Coordinating Center autopsy cohort across the entire clinicopathological continuum of AD. Multivariate models were built to examine the associations between APOE alleles and AD neuropathological changes, using the APOE 3/ 3 group as comparator. Mediation analysis was used to estimate the direct and indirect effects of APOE alleles on AD pathology and cognition (Clinical Dementia Rating Sum of Boxes and Mini-Mental State Examination). Results Compared to APOE 3/ 3, APOE 2 is independently associated with lower Braak neurofibrillary tangle (NFT) stages and possibly fewer neuritic plaques, but has no direct effect on cerebral amyloid angiopathy (CAA) severity, whereas APOE 4 is associated with more neuritic plaques and CAA, but has no independent effect on Braak NFT stage. Unadjusted analyses showed marked differences among APOE genotypes with respect to cognitive performance ( 2 > 3 > 4). Mediation analysis suggests that this is largely explained through effects on pathology. Interpretation Even when adjusted for age at onset, symptom duration, and other demographic variables, APOE 2 is associated with milder AD pathology and less severe antemortem cognitive impairment compared to APOE 3 and 4 alleles, suggesting a relative neuroprotective effect of APOE 2 in AD. Ann Neurol 2015;77:917-929

UR - http://www.scopus.com/inward/record.url?scp=84930014969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930014969&partnerID=8YFLogxK

U2 - 10.1002/ana.24369

DO - 10.1002/ana.24369

M3 - Article

VL - 77

SP - 917

EP - 929

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 6

ER -